A comparative study of midazolam and target-controlled propofol infusion in the treatment of refractory status epilepticus
Dheeraj Masapu, K. N. Gopala Krishna, Sinha Sanjib, Dhrithiman Chakrabarti, R. C. Mundlamuri, Nitin Manohar, P. Mariamma, P. Satishchandra, G. S. Umamaheswara Rao
Midazolam, outcome, propofol, refractory status epilepticus, super refractory status, target-controlled infusion
Citation Information :
Masapu D, Gopala Krishna KN, Sanjib S, Chakrabarti D, Mundlamuri RC, Manohar N, Mariamma P, Satishchandra P, Umamaheswara Rao GS. A comparative study of midazolam and target-controlled propofol infusion in the treatment of refractory status epilepticus. Indian J Crit Care Med 2018; 22 (6):441-448.
Background: The recommended treatment for refractory status epilepticus (RSE) is the use of anesthetic agents, but evidence regarding the agent of choice is lacking. This study was designed to compare target-controlled infusion of propofol versus midazolam for the treatment of RSE regarding seizure control and complications.
Methods: This prospective, randomized study recruited 23 adult patients with RSE due to any etiology and treated with either propofol or midazolam titrated to clinical seizure cessation and gradual tapering thereafter. The primary outcome measure was seizure control and the secondary outcomes were duration of the Intensive Care Unit stay and duration of mechanical ventilation, occurrence of super RSE (SRSE), and complications.
Results: We recruited 23 patients (male:female = 18:5) into this study (propofol Group-11; midazolam Group-12). Overall, seizure control was noted in 34.8%, with successful seizure control in 45% of patients in the propofol group and 25% in midazolam group (P = 0.4). Mortality was similar in both the groups (propofol group [8/11; 72.7%] compared to the midazolam group [7/12; 58.3%] [P = 0.667]). The duration of hospital stay was significantly shorter in the propofol group compared to midazolam (P = 0.02). The overall incidence of SRSE was 69.5% in this study. The complication rate was not significantly different between the groups.
Conclusions: The choice of anesthetic agent does not seem to affect the overall outcome in RSE and SRSE. Target-controlled propofol infusion was found to be equal in its efficacy to midazolam for the treatment of RSE. High mortality might be due to SRSE secondary to the underlying brain pathology.
Kang BS, Jung KH, Shin JW, Moon JS, Byun JI, Lim JA, et al. Induction of burst suppression or coma using intravenous anesthetics in refractory status epilepticus. J Clin Neurosci 2015;22:854-8.
Rossetti AO, Logroscino GB. Refractory status epilepticus: Is EEG burst suppressin an appropriate treatment target during drug induced coma? What is the holy grail? Epilepsy Curr 2006;6:119-20.
Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012;17:3-23.
Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF, et al. Refractory status epilepticus: Frequency, risk factors, and impact on outcome. Arch Neurol 2002;59:205-10.
Mundlamuri RC, Sinha S, Subbakrishna DK, Prathyusha PV, Nagappa M, Bindu PS, et al. Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam – Pilot study. Epilepsy Res 2015;114:52-8.
Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 2012;135:2314-28.
Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain 2011;134:2802-18.
Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: Still more questions than answers. Lancet Neurol 2011;10:922-30.
Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: A prospective observational study. Epilepsia 2010;51:251-6.
Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW, et al. Arandomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2011;14:4-10.
Cortínez LI, De la Fuente N, Eleveld DJ, Oliveros A, Crovari F, Sepulveda P, et al. Performance of propofol target-controlled infusion models in the obese: Pharmacokinetic and pharmacodynamic analysis. Anesth Analg 2014;119:302-10.
Lei X, Yan Li Z, Yu Lei G, Jie Z, En You L, Fu Jun Q, et al. Determination of the plasma propofol concentrations in surgical patients and evaluation of the target-controlled infusion system. Pharm Care Res 2015;15:134-7.
Prabhakar H, Bindra A, Singh GP, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database Syst Rev. 2012;(8):7-8.
Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001;42:380-6.
Parviainen I, Uusaro A, Kälviäinen R, Mervaala E, Ruokonen E. Propofol in the treatment of refractory status epilepticus. Intensive Care Med 2006;32:1075-9.
Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol 2002;17:106-10.
Stecker MM, Kramer TH, Raps EC, O'Meeghan R, Dulaney E, Skaar DJ, et al. Treatment of refractory status epilepticus with propofol: Clinical and pharmacokinetic findings. Epilepsia 1998;39:18-26.
Anand Kumar M, Thomas P, Bleck M. Midaz infusion in refractory status epilepticus. Crit Care Med 1992;20:483-8.
Rossetti AO, Reichhart MD, Schaller MD, Despland PA, Bogousslavsky J. Propofol treatment of refractory status epilepticus: A study of 31 episodes. Epilepsia 2004;45:757-63.
Giovannini G, Monti G, Polisi MM, Mirandola L, Marudi A, Pinelli G, et al. Aone-year prospective study of refractory status epilepticus in Modena, Italy. Epilepsy Behav 2015;49:141-5.
Jayalakshmi S, Ruikar D, Vooturi S, Alladi S, Sahu S, Kaul S, et al. Determinants and predictors of outcome in super refractory status epilepticus – A developing country perspective. Epilepsy Res 2014;108:1609-17.
Sinha S, Satishchandra P, Mahadevan A, Bhimani BC, Kovur JM, Shankar SK, et al. Fatal status epilepticus: A clinico-pathological analysis among 100 patients: From a developing country perspective. Epilepsy Res 2010;91:193-204.
Parviainen I, Uusaro A, Kälviäinen R, Kaukanen E, Mervaala E, Ruokonen E, et al. High-dose thiopental in the treatment of refractory status epilepticus in Intensive Care Unit. Neurology 2002;59:1249-51.
Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: An 11-year clinical experience. Crit Care Med 2009;37:3024-30.
Sinha S, Prashantha DK, Thennarasu K, Umamaheshwara Rao GS, Satishchandra P. Refractory status epilepticus: A developing country perspective. J Neurol Sci 2010;290:60-5.
Fernandez A, Lantigua H, Lesch C, Shao B, Foreman B, Schmidt JM, et al. High-dose midazolam infusion for refractory status epilepticus. Neurology 2014;82:359-65.
Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998;338:970-6.